{
C4 Therapeutics Inc.

Companies

}
001122334455554433221100
001122334455554433221100

ubs lowers c4 therapeutics price target while maintaining neutral rating

UBS has lowered its price target for C4 Therapeutics, Inc. to $3.50 from $4 while maintaining a neutral rating. The clinical-stage biopharmaceutical company focuses on targeted protein degradation, utilizing its TORPEDO platform to develop small-molecule medicines, including candidates CFT7455 and CFT1946 for various cancers.
MarketScreener
C4 Therapeutics Inc. USA
Healthcare & Medicine, Market Report
14:26 03.03.2025
Trending
Subcategory:
Corporate News Stock Market Updates Industry Trends Retail and Consumer Goods Finance Mergers & Acquisitions Financial Scams and Security Market Analysis and Predictions Startups & Entrepreneurship Global Financial Events Banking Regulations CEO Changes Industry Mergers & Acquisitions Real Estate Investments Workplace Trends Telecommunications Laws Anti-Money Laundering (AML) Regulations Consumer Protection Regulations Energy Sector Developments Central Bank Actions Supply Chain Management
Countries:
USA CHN CHE IND BEL DEU PRT GBR ARE FRA CAN SAU HKG JPN SGP KOR ISR BRA MEX CHL
Companies:
UBS AG Google Inc. Raymond James Financial Inc. PostFinance AG Southern Copper Corporation Knight Frank LLP The Goldman Sachs Group, Inc. puma.bär GmbH Allfunds Group plc Berner Kantonalbank HUGO BOSS AG Microsoft Corporation Corp. Fidelity Management & Research Company LLC Tiger Global Management LLC Robert W. Baird & Co. Inc. Emirates NBD PAO Dell Technologies Inc. Etihad Airways Purple Style Labs Ltd. Meituan
Currencies:
United States Dollar Euro Swiss Franc Chinese Yuan Indian Rupee British Pound Sterling Japanese Yen Singapore Dollar South Korean Won United Arab Emirates Dirham New Taiwan Dollar Saudi Riyal Omani Rial Australian Dollar Turkish Lira Polish Złoty Russian Ruble
People:
Donald Trump Elon Musk Valerio Ottati Joe Biden Howard Lutnick Daniel Freund Michela Ferrari-testa Patrick Hummel Robert Krankowski Sanjeev Kapoor Faisal Durrani Susan Amawi Mike Waltzer Richard Yu Nicholas Aiossa Urs Monstein Barbara Ofner Stephan Ochsner Paul Simao Sudip Kar-gupta

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.